Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was ...

Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Fintel reports that on April 28, 2025, Cantor Fitzgerald initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the ...

Viking Therapeutics, Inc.’s VKTX share price has surged by 5.65%, which has investors questioning if this is right time to ...

Viking Therapeutics ( NASDAQ: VKTX) posted a wider than expected loss for the first quarter, pushing shares lower, as the ...

Viking TherapeuticsVKTX reported a first-quarter 2025 loss of 41 cents per share, wider than the Zacks Consensus Estimate of ...

All that being said, until the actual clinical trial data comes out, it's impossible to say for sure that the drug will be a success, or that Viking Therapeutics stock will go up as far and as ...